| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| AN2 Therapeutics, Inc. | Director | Common Stock | 8.61K | $10.1K | $1.18 | May 28, 2025 | Direct |
| AN2 Therapeutics, Inc. | Director | Stock Option (Right to Buy) | 19.1K | May 22, 2025 | Direct | ||
| Vistagen Therapeutics, Inc. | Director | Non-Qualified Stock Option (right to buy) | 17.6K | Sep 9, 2025 | Direct |